Connect with us

Sovereign Funds Ramp Up Healthcare Investments

Published

on

With the United States experiencing an economic recovery, the healthcare industry is expected to prosper as it remains a significant proportion of the country’s gross domestic product (GDP). Sovereign investors are increasing positions in health-related industries such as pharmaceuticals, genome analysis and diagnostic technologies, while large Canadian pension plans have been investing in specialty healthcare chains.


May 11, 2017 Correction, the earlier graph had billions, it should be millions.

Sovereign funds continue to tap their extensive deal network when it comes to identifying large-scale healthcare opportunities in the United States. Many of these sovereign funds, such as the Abu Dhabi Investment Authority (ADIA), are limited partners in private equity funds that target pharmaceuticals and healthcare companies. For example, in April, ADIA and Singapore’s GIC Private Limited acquired minority ownership interests in Pharmaceutical Product Development, LLC (PPD), a clinical research company based in North Carolina. The recapitalization deal scored PPD at an enterprise value of US$ 9.05 billion. In a much smaller investment transaction, Australia’s Future Fund participated in a US$ 200 million growth equity funding round into El Segundo, California-based Radiology Partners. Radiology Partners claims it’s the largest on-site physician-led radiology practice in the United States.

According to data from the Sovereign Wealth Fund Institute (SWFI), sovereign funds directly invested over US$ 6.2 billion into the global health care sector in 2016. This figure does count externally-managed funds or private fund vehicles. In 2015, wealth funds directly invested US$ 6.9 billion and in 2014 directly invested US$ 4.3 billion. In the final quarter of 2016, direct investments by sovereign investors into healthcare was buoyed by global equity markets.

Pharmaceuticals

Pharmaceuticals have always intrigued sovereign funds. For example, in mid-to-late 2016, Norway’s Government Pension Fund Global (GPFG), in the open market, invested well over US$ 100 million into Abbott Laboratories. In the summer of 2016, the Korea Investment Corporation (KIC) had partnered with CDC International Capital, the multi-asset class investment company of the Caisse des Dépôts Group to back Ethypharm, a specialty pharmaceuticals company focus on treating pain and addictions. Permanent funds such as the Alaska Permanent Fund Corporation invested in South San Francisco-based Denali Therapeutics Inc. in 2016. Denali Therapeutics is constructing a portfolio of therapeutics, focusing in areas such as the triggers or effectors of neurodegeneration. AFPC has a track record of backing emerging pharmaceutical companies such as Seattle-based Juno Therapeutics. All in all, the trend line shows that wealth fund capital is not backing away from the healthcare sector.

PGGM Executed its Inaugural Cleared Securities Lending Trade

Published

on

Service providers are keen on getting more beneficial owners to participate in the cleared securities lending market. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Continue Reading

Altitude Infrastructure Gets Financing on Haute-Garonne Network Project

Published

on

Altitude Infrastructure SAS inked a 25-year concession agreement and closed a debt financing package for the deployment and maintenance of an ultra-high-speed broadband network in Haute-Garonne. Haute-Garonne is a department in the south of France.[ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Continue Reading

Guggenheim Partners Agrees to Acquire Millstein & Co.

Published

on

On July 11, 2018, Guggenheim Partners inked a deal to acquire New York-based Millstein & Co., L.P., an advisory firm formed by Jim Millstein. Millstein will become co-Chairman of Guggenheim’s securities business. Millstein & Co. will become part of Guggenheim Securities, the investment banking division of the company. Ronen Bojmel will lead the combined Guggenheim restructuring team.

[ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Continue Reading

Popular

© 2008-2018 Sovereign Wealth Fund Institute. All Rights Reserved. Sovereign Wealth Fund Institute ® and SWFI® are registered trademarks of the Sovereign Wealth Fund Institute. Other third-party content, logos and trademarks are owned by their perspective entities and used for informational purposes only. No affiliation or endorsement, express or implied, is provided by their use. All material subject to strictly enforced copyright laws. Registration on or use of this site constitutes acceptance of our terms of use agreement which includes our privacy policy. Sovereign Wealth Fund Institute (SWFI) is a global organization designed to study sovereign wealth funds, pensions, endowments, superannuation funds, family offices, central banks and other long-term institutional investors in the areas of investing, asset allocation, risk, governance, economics, policy, trade and other relevant issues. SWFI facilitates sovereign fund, pension, endowment, superannuation fund and central bank events around the world. SWFI is a minority-owned organization.